JP2021525509A5 - - Google Patents

Info

Publication number
JP2021525509A5
JP2021525509A5 JP2020566230A JP2020566230A JP2021525509A5 JP 2021525509 A5 JP2021525509 A5 JP 2021525509A5 JP 2020566230 A JP2020566230 A JP 2020566230A JP 2020566230 A JP2020566230 A JP 2020566230A JP 2021525509 A5 JP2021525509 A5 JP 2021525509A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
protein
cancer
cell
Prior art date
Application number
JP2020566230A
Other languages
English (en)
Japanese (ja)
Other versions
JP7599205B2 (ja
JPWO2019232503A5 (https=
JP2021525509A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035096 external-priority patent/WO2019232503A1/en
Publication of JP2021525509A publication Critical patent/JP2021525509A/ja
Publication of JPWO2019232503A5 publication Critical patent/JPWO2019232503A5/ja
Publication of JP2021525509A5 publication Critical patent/JP2021525509A5/ja
Priority to JP2024039934A priority Critical patent/JP2024073564A/ja
Application granted granted Critical
Publication of JP7599205B2 publication Critical patent/JP7599205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566230A 2018-06-01 2019-06-01 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 Active JP7599205B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024039934A JP2024073564A (ja) 2018-06-01 2024-03-14 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679741P 2018-06-01 2018-06-01
US62/679,741 2018-06-01
PCT/US2019/035096 WO2019232503A1 (en) 2018-06-01 2019-06-01 Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024039934A Division JP2024073564A (ja) 2018-06-01 2024-03-14 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化

Publications (4)

Publication Number Publication Date
JP2021525509A JP2021525509A (ja) 2021-09-27
JPWO2019232503A5 JPWO2019232503A5 (https=) 2022-06-07
JP2021525509A5 true JP2021525509A5 (https=) 2022-06-07
JP7599205B2 JP7599205B2 (ja) 2024-12-13

Family

ID=68697132

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566230A Active JP7599205B2 (ja) 2018-06-01 2019-06-01 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
JP2024039934A Pending JP2024073564A (ja) 2018-06-01 2024-03-14 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024039934A Pending JP2024073564A (ja) 2018-06-01 2024-03-14 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化

Country Status (16)

Country Link
US (1) US20210137977A1 (https=)
EP (1) EP3802822A4 (https=)
JP (2) JP7599205B2 (https=)
KR (1) KR20210057705A (https=)
CN (1) CN113286879B (https=)
AU (2) AU2019279084B2 (https=)
BR (1) BR112020024246A2 (https=)
CA (1) CA3101510A1 (https=)
CO (1) CO2020016586A2 (https=)
EA (1) EA202092945A1 (https=)
IL (2) IL279100B2 (https=)
MX (1) MX2020012927A (https=)
SG (1) SG11202011837UA (https=)
TW (1) TW202018083A (https=)
WO (1) WO2019232503A1 (https=)
ZA (2) ZA202007393B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
MX2020004185A (es) 2017-09-27 2021-01-08 Univ Southern California Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
EP3733707A1 (en) * 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
EP4041256A4 (en) * 2019-10-10 2023-11-08 Arizona Board of Regents on behalf of Arizona State University Oncolytic viruses that express multi-specific immune cell engagers
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
US20230060351A1 (en) * 2020-01-08 2023-03-02 Board Of Regents, The University Of Texas System A method of engineering natural killer cells to target cd70-positive tumors
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
KR20230009386A (ko) * 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
IL297553A (en) * 2020-04-24 2022-12-01 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting cd19 and their use
TW202208412A (zh) * 2020-05-06 2022-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 對酪胺酸蛋白激酶樣７（ｐｔｋ７）特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
EP4168046A4 (en) * 2020-06-18 2024-10-16 Nextcure, Inc. COMPOSITIONS AND METHODS FOR MODULATING FLRT3-MEDIATED SIGNAL TRANSDUCTION
CN116490208A (zh) * 2020-08-06 2023-07-25 史坦利科西斯治疗有限责任公司 Il-8抗体及其使用方法
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
CA3201008A1 (en) * 2020-12-02 2022-06-09 Shanghai Cellular Biopharmaceutical Group Ltd. Bcma-targeted chimeric antigen receptors
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
AU2022227021A1 (en) * 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
CN115491358B (zh) * 2021-06-17 2024-09-06 复星凯特生物科技有限公司 一种靶向b7-h3和folr1双打靶点car t的制备及应用
TW202330595A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
CN114106199B (zh) * 2021-11-19 2022-07-12 广州百暨基因科技有限公司 靶向adgre2的嵌合抗原受体及其应用
WO2023147784A1 (zh) * 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
WO2023170549A1 (en) * 2022-03-07 2023-09-14 Medimmune Llc Treatment methods using ctla-4 and pd-1 bispecific antibodies
WO2023175069A1 (en) * 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs
EP4493583A1 (en) * 2022-03-16 2025-01-22 Medigene Immunotherapies GmbH Tcr constant region pairing library
GB202208119D0 (en) * 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024136899A1 (en) * 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
GB202301421D0 (en) * 2023-02-01 2023-03-15 Univ Oslo Hf Switch receptor for use in adoptive cell therapy
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
WO2024220834A1 (en) * 2023-04-19 2024-10-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Car-t cells co-expressing cd40l
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025151607A1 (en) * 2024-01-10 2025-07-17 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
WO2015158671A1 (en) * 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI750110B (zh) * 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
WO2016174852A1 (ja) * 2015-04-30 2016-11-03 株式会社デンソー 蒸発器
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
EP3479003B1 (en) 2016-06-30 2023-11-01 Illinois Tool Works Inc. Device for holding an electronic gadget
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
MX2020004185A (es) 2017-09-27 2021-01-08 Univ Southern California Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
AU2022224066A1 (en) * 2021-02-19 2023-09-07 Angeles Therapeutics, Inc. Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Similar Documents

Publication Publication Date Title
JP2021525509A5 (https=)
JPWO2019232503A5 (https=)
JPWO2021188599A5 (https=)
JP2021500861A5 (https=)
JP2020500530A5 (https=)
JP7487112B2 (ja) Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2025037871A5 (https=)
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
IL297514A (en) Vectors and methods for in vivo transduction
CN113227379A (zh) 多功能多靶向嵌合抗原受体（car）系统及其使用方法
JP2017513818A5 (https=)
JP2019503200A (ja) 癌の治療のための組成物及び方法
JP2018532432A5 (https=)
AU2021307614A1 (en) Engineered immune cell for allotransplantation
JP2020517263A5 (https=)
US20220152101A1 (en) Cellular immunotherapy combination
JPWO2022178367A5 (https=)
KR20240032732A (ko) 암 면역요법을 위한 투약 요법
KR20240033025A (ko) Bcma-지시된 세포 면역요법 조성물 및 방법
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
JP2025524564A (ja) Ｃｄ１９指向性がん免疫療法の投与レジメン
JPWO2021231505A5 (https=)
WO2022267983A1 (zh) 工程化免疫细胞及其用途
JPWO2022241036A5 (https=)